Balakrishnan, M., George, R., Sharma, A., & Graham, D. Y. (2017).

Changing
Trends in Stomach Cancer Throughout the World. Current Gastroenterology
Reports, 19(8)

(1.. Ferlay J., Soerjomataram I., Ervik M., Dikshit R., Eser S., Mathers C., Rebelo
M., Parkin D., Forman D., Bray F. GLOBOCAN 2012 v1.0, Cancer Incidence and
Mortality Worldwide: IARC CancerBase No. 11. )

2. Bray F., Ferlay J., Soerjomataram I..,et al (2018). Global cancer statistics 2018:
GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in
185 countries. 1-31.

3. Ajani, J. A., Lee, J., Sano, T., Janjigian, Y. Y., Fan, D., & Song, S.
(2017). Gastric adenocarcinoma. Nature Reviews Disease Primers, 3, 17036
4. Ansari, S., Gantuya, B., Tuan, V., & Yamaoka, Y. (2018). Diffuse Gastric
Cancer: A Summary of Analogous Contributing Factors for Its Molecular
Pathogenicity. International Journal of Molecular Sciences, 19(8), 2424.
5. Oliveira, C., et al. (2004), Genetic screening for familial gastric cancer. Hered
Cancer Clin Pract, 2(2), 51-64.
6. Corso G1, Pedrazzani C, Pinheiro H, (2010), E-cadherin genetic screening and
clinico-pathologic characteristics of early onset gastric cancer.,
7.Liu, X., & Chu, K.-M. (2014). E-Cadherin and Gastric Cancer: Cause,
Consequence, and Applications. BioMed Research International, 2014, 1–9.
8. Mateus AR, Simões-Correia J, Figueiredo J, (2009), E-cadherin mutations and
cell motility: a genotype–phenotype correlation, 315: 1393–402.,
9. Machado, J. C., Oliveira, C., Carvalho, R., Soares, P., Berx, G., Caldas, C., …
Sobrinho-Simöes, M. (2001). E-cadherin gene (CDH1) promoter methylation as
the second hit in sporadic diffuse gastric carcinoma. Oncogene, 20(12).
10. Grady WM, Willis J, Guilford PJ, et al. (2006) Methylation of the CDH1
promoter as the second genetic hit in hereditary diffuse gastric cancer.:16–17.
11. Yamamoto, E., Suzuki, H., Takamaru, H., Yamamoto, H., Toyota, M., &
Shinomura, Y. (2011). Role of DNA Methylation in the Development of Diffuse-
Type Gastric Cancer. Digestion, 83(4), 241–249
12.Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D.
(2011). Global cancer statistics. CA: A Cancer Journal for Clinicians, 61(2), 69–90
13. GLOBOCAN. (2018). <http://gco.iarc.fr/today/home>, [Accessed 12.09.2018].
14. Bosman FT, World Health Organization and International Agency for Research
on Cancer (2010). WHO classification of tumours of the digestive system,
International Agency for Research on Cancer, Lyon.
15.Marqués-Lespier, J. M., González-Pons, M., & Cruz-Correa, M. (2016). Current
Perspectives on Gastric Cancer. Gastroenterology Clinics of North America, 45(3),
413–428.
16. Fact Sheets by Population.
<http://globocan.iarc.fr/Pages/fact_sheets_population.aspx>, accessed: 21/06/2018.
17. Lại Phu Thưởng (2006). Tình hình ghi nhận ung thư giai đoạn 2001 - 2004
qua giai đoạn ghi nhận tại 5 tỉnh thành Việt Nam. Tạp chí y học thực hành, 9 (17),
18. Nguyễn Bá Đức. Lại Phu Thưởng, Nguyễn Thị Hoài Nga (2006). Tình hình
ghi nhận ung thư giai đoạn 2001 - 2004 qua giai đoạn ghi nhận ung thư tại 5 tỉnh
thành Việt Nam. Tạp chí y học thực hành, 9 - 17.
19. Hoàng Trọng Thảng (2006). Ung thư dạ dày,
20. Kim M.A., Yang H.K., Kim W.H..,et al (2005). Clinicopathologic and protein
expression differences between cardia carcinoma and non-cardia carcinoma of
the stomach. Cancer, 103 (7), 1430-1446.
21. Deans, C., et al. (2011), Cancer of the gastric cardia is rising in incidence in an
Asian population and is associated with adverse outcome. World J Surg, 35(3),
617-24.
22.McColl, K.E. (2006), Cancer of the gastric cardia. Best Pract Res Clin
Gastroenterol, 20(4), 687-96.
23. Bomarn Stemmermann G.N., Fenoglio-Preiser C.M., (2008), “Gastric Cancer:
Pathology”, Principles and practice of gastrointestinal oncology, 2nd ed, Lippincott
Williams & Wilkins: pp. 257-274.
24. Association, J.G.C. (2011), Japanese classification of gastric carcinoma.
Gastric Cancer, 14, 101-112.
25. Lauren P (1965). The two histological main types of gastric carcinoma: diffuse
and so-called intestinal-type carcinoma. An attempt at a histo-clinical
classification. Acta Pathol Microbiol Scand, 64, 31-49.
26. Lazăr D, Tăban S, Sporea I.,et al (2009). Gastric cancer: Correlation between
clinicopathological factors and survival of patients. Romanian Journal of
Morphology and Embryology, 50 (2), 185-194.
.
TLTK phần Methyl

1. Cancer epigenetics: linking basic biology to clinical medicine. Cell Res

21:502–517
2. Cancer epigenetics: an introduction.
3. Epigenetics and cancer.
Phần yếu tố nguy cơ

28. Pizzi M, Saraggi D, Fassan M, et al (2014), Secondary prevention of epidemic

gastric cancer in the model of Helicobacter pylori-associated gastritis., Dig Dis,
32.

29. Vũ Quang Toản, Đoàn Hữu Nghị, Đỗ Anh Tu (2015), Điều trị ung thư dạ dày
tiến triển tại chỗ bằng phẫu thuật và hóa trị bổ trợ EOX, Tạp chí Y học lâm sàng,
số 29/2015.

30.Vũ Quang Toản, Đoàn Hữu Nghị, Đỗ Anh Tu, Trần Văn Tuấn, and Nguyễn Thị
Hải Anh, Nguyễn Quỳnh Hương (2013), Đánh giá kết quả nội soi - sinh thiết và
mô bệnh học sau phẫu thuật ung thư dạ dày tiếnvtriển tại chỗ (IIB-IIIC: T4, M0),
Tạp chí Ung thư học Việt Nam, số 4/2013,.

31,32. M. Rugge, M. Fassan và D. Y. Graham (2015). Epidemiology of gastric

cancer. Gastric Cancer, Springer, 23-34.
33,34. T. L. Ang và K. M. Fock (2014). Clinical epidemiology of gastric
cancer. Singapore medical journal, 55 (12), 621.
35. Helicobacter và C. C. Group (2001). Gastric cancer and Helicobacter pylori: a
combined analysis of 12 case control studies nested within prospective
cohorts. Gut, 49 (3), 347-353.
36,37. P. Q. Cử (1999). Mối liên quan giữa nhiễm Helicobacter Pylori với
viêm teo, di sản ruột, loạn sản ruột và ung thư dạ dày. Học viện Quân Y,
20(38). Đ. T. V. K. Trần Văn Huy, Phan Trung Nam, Đặng Công Thuận, Ngô Văn
Trung, Trần Thị Phương Thảo, Huỳnh Thị Như Ý, Đoàn Thị Sâm (2006).
Nghiên cứu đặc điểm nội soi, mô bệnh học và tỷ lệ nhiễm Helicobacter pylori
ở các bệnh nhân ung thư dạ dày ở Bệnh viện Trường Đại học Y khoa Huế.
Trường Đại học Y Dược Huế,
20(39). Nguyễn Thị Hương (2006), Nghiên cứu đặc điểm lâm sàng, cận lâm
sàng và kết quả điều trị phẫu thuật ung thư dạ dày sớm tại bệnh viên K.
Luận văn tốt nghiệp bác sĩ nội tru-Đại học Y Hà Nội.
40. Leung, W.K., Ng, E.K.W., Sung, J.J.Y. (2009), Tumors of the Stomach.
Textbook of gastroenterologyogy, 1026-1053.
41. Tạ Long, Trịnh Tuấn Dũng, Nguyễn Quang Chung và cộng sự (2006),
Nghiên cứu mối liên quan giữa ung thư dạ dày và nhiễm khuẩn Helicobacter
pylori. Tạp chí Khoa học Tiêu hóa Việt Nam, 1,10-19.
32(42,44,47,54,58,63). Pisters PWT, Kelsen DP, and Tepper JE (2008), Cancer
of the Stomach, Cancer: Principles and practice of oncology, 8th edition,
Lippincott William and Wilkins., .

43. Ang T.L. and Fock K.M. (2014). Clinical epidemiology of gastric cancer.
Singapore Med J, 55(12), 621–628.

41. Shiotani A, Cen P and Graham DY (2013). Eradication of gastric cancer is now
both possible and practical. Semin Cancer Biol, 23, 492-501.
45. Abrams J. A and Wang T.C (2010). Adenocarcinoma and other Tumors of the
Stomach. Sleisenger and Fordtran's gastrointestinal and liver disease:
pathophysiology/diagnosis/management, 9th ed, Saunders, Philadelphia, 887-908.
46. Hoàng Trọng Thảng (2006). Bệnh Tiêu hóa- Gan mật, Nhà Xuất Bản Y học, Hà
Nội.
37(48) Nomura A.M.Y., Wilkens L.R., Henderson B.E., et al. (2012). The
association of cigarette smoking with gastric cancer: the multiethnic cohort study.
Cancer Causes Control, 23(1), 51–58.

38(49). , 66(6), 1054–1064.

26(50). P. G. Gonzalez C.A., Agudo A. et al. (2003). Smoking and the risk of
gastric cancer in the European Prospective Investigation into Cancer and
Nutrition (EPIC). International Journal of Cancer, 107, pp. 629-634.
27(51,52). P. A. Jayalekshmi, S. Hassani, A. Nandakumar và cộng sự (2015).
Gastric cancer risk in relation to tobacco use and alcohol drinking in Kerala,
India-Karunagappally cohort study. World journal of gastroenterology, 21
(44), 12676.
28(53). S. S. Mirvish (1995). Role of N-nitroso compounds (NOC) and N-
nitrosation in etiology of gastric, esophageal, nasopharyngeal and bladder cancer
and contribution to cancer of known exposures to NOC. Cancer letters, 93 (1), 17-
48.

40(55). .

36. Correa P (2014), Pathology and molecular pathogenesis of gastric

cancer,UpToDate, Jul 2014, version 14.0, .

Guilford, P.J., et al. (1999), E-cadherin germline mutations define an inherited

cancer syndrome dominated by diffuse gastric cancer. Hum Mutat, 14(3),
249-55.
8(57). Guilford, P., et al. (1998), E-cadherin germline mutations in familial gastric
cancer. Nature, 392(6674), 402-5.
44 hoàng Ngọc Thảng
25(62). Calle, E.E., et al. (2003), Overweight, obesity, and mortality from
cancer in a prospectively studied cohort of U.S. adults. N Engl J Med,
348(17), 1625-38.
21(73,74). Leung WK, Ng EKW and Sung JJY (2009), Tumors of the stomach.
Textbook of Gastroenterology, 5th Edition, Wiley-Blackwell, .====21 trên ===21
PT
32. C. W. H. Freedman N.D., Gao Y.T., et al. (2007). Menstrual and reproductive
factors and gastric cancer risk in a large prospective study of women. Gut, 56,
pp. 1671-1677.
26(64). Đỗ Đức Vân (1993), Điều trị phẫu thuật ung thư dạ dày tại bệnh viện
Việt Đức (1970-1992). Y học Việt Nam, 7(173), 45-50.
29(65,68). N. E. K. W. Leung W.K., Sung J. J. Y (2009). Tumors of the stomach,
Blackwell Publishing. == soi ổ bụng
47(66,69,70,71,72,75,79,84,85). Nguyễn Văn Hiếu (2015), Ung thư học, Nhà
xuất bản Y học. = siêu âm nội soi== Pet ct== PT== hóa trị

51(77). NCCN (2015), Gastric cancer, NCCN Clinical Practice Guidelines in

Oncology, V 3, .

45(78). Trần Thiện Trung (2014), “ Ung thư dạ dày, bệnh sinh, chẩn đoán,
điều trị,” Nhà xuất bản Y học.

29(76). Vũ Quang Toản, Đoàn Hữu Nghị, Đỗ Anh Tu, Trần Văn Tuấn, and
Nguyễn Thị Hải Anh, Nguyễn Quỳnh Hương (2013), Đánh giá kết quảvnội soi -
sinh thiết và mô bệnh học sau phẫu thuật ung thư dạ dày tiếnvtriển tại chỗ (IIB-
IIIC: T4, M0), Tạp chí Ung thư học Việt Nam, số 4/2013,.
..Nguyễn Phúc Cương, Trịnh Quốc Hoàn (2001), Nghiên cứu hình ảnh giải phẫu bệnh học của Ung thư dạ
dày-Tài liệu hội thảo lần 2. Trung tâm hợp tác nghiên cứu của Tổ chức Y tế Thế giới về ung thư dạ dày,

57. Ohtsu, A. (2008), Chemotherapy for metastatic gastric cancer: past, present, and future. J
Gastroenterol, 43(4), 256-64.

84(81). Andrew M. Scott, James P. Allison and Jedd D. Wolchok (2012).

Monoclonal antibodies in cancer therapy. Cancer Immunity, 12, 14-22.
10(82). Bang YJ, Van Cutsem E, Feyereislova A.,et al (2010). Trastuzumab in
combination with chemotherapy versus chemotherapy alone for treatment of
HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a
phase 3, open-label, randomised controlled trial. Lancet, 376 (9742), 687-697.
85(83). Uhi Toh, Tetsuro Sasada, Ryuji Takahashi.,et al (2015). Tumor
Immunotherapy of Esophageal and Gastric Cancers. Cancer Immunology Cancer
Immunotherapy for Organ- Specific Tumors, Springer, 185-197.
59(86). Kirkwood JM1, Butterfield LH, Tarhini AA, Zarour H, Kalinski P,
Ferrone S. (2012). Immunotherapy of cancer in 2012. .
[.]B. O’Sullivan (2015), UICC Manual of Clinical Oncology, John Wiley & Sons, Chichester, UK., .

[//]TNM staging of stomach carcinomas (AJCC 8th edition)

36(87). Benson, A.B. (2008), Advanced gastric cancer: an update and future
directions. Gastrointest Cancer Res, 2(4 Suppl), S47-53.
37(88). Li, C., et al. (2009), Macroscopic Borrmann type as a simple
prognostic indicator in patients with advanced gastric cancer. Oncology,
77(3-4), 197-204.
38(89). Galizia, G., et al. (2007), Epidermal growth factor receptor (EGFR)
expression is associated with a worse prognosis in gastric cancer patients
undergoing curative surgery. World J Surg, 31(7), 1458-68.
39(90). Kataoka, Y., et al. (2013), HER2 expression and its
clinicopathological features in resectable gastric cancer. Gastric Cancer,
16(1), 84-93.
Phần UTDD lan tỏa liên quan CDH1

66. Pardeep Kaurah, MSc, CCGC and David G Huntsman, MD, (2014), Hereditary
Diffuse Gastric Cancer, GeneReviews.,
67. Oliveira, C., R. Seruca, and F. Carneiro (2006), Genetics, pathology, and clinics
of familial gastric cancer. Int J Surg Pathol, 14(1), 21-33.
68. Kaurah, P., et al. (2007), Founder and recurrent CDH1 mutations in families with
hereditary diffuse gastric cancer. JAMA, 297(21), 2360-72.
Shah, Ma
66
69. Shah, M., Salo-Mullen, E., Stadler, Z., Ruggeri, J., Mirander, M.,
Pristyazhnyuk, Y., & Zhang, L. (2011). De novo CDH1 mutation in a family
presenting with early-onset diffuse gastric cancer. Clinical Genetics, 82(3),
283–287.
70. Gayther SA, Gorringe KL, Ramus SJ,. Identification of germ-line E-cadherin
mutations in gastric cancer families of European origin. Cancer Res.
1998;58:4086–9.

71. Blair, V., et al. (2006), Hereditary diffuse gastric cancer: diagnosis and
management. Clin Gastroenterol Hepatol, 4(3), 262-75.

72. Bing Hu , Nassim El Hajj , Scott Sittler , Nancy Lammert , Robert Barnes ,
Aurelia Meloni-Ehrig, (2012), Gastric cancer: Classification, histology and
application of molecular pathology

73. Oliveira, C., R. Seruca, and F. Carneiro (2009), Hereditary gastric cancer. Best
Pract Res Clin Gastroenterol, 23(2), 147-57.

49.Guilford, P.J., et al. (1999), E-cadherin germline mutations define an inherited

cancer syndrome dominated by diffuse gastric cancer. Hum Mutat, 14(3), 249-55.

50.Guilford, P., et al. (1998), E-cadherin germline mutations in familial gastric

cancer. Nature, 392(6674), 402-5.
74.Graziano, F., B. Humar, and P. Guilford (2003), The role of the E-cadherin gene
(CDH1) in diffuse gastric cancer susceptibility: from the laboratory to clinical
practice. Ann Oncol, 14(12), 1705-13.
40(75).Takeichi, M. (1995), Morphogenetic roles of classic cadherins. Curr Opin Cell Biol, 7(5), 619-27.

46(76) Xin Liu and Kent-Man Chu, (2014), Review Article E-Cadherin and Gastric Cancer: Cause,
Consequence, and Applications, BioMed Research International Volume 2014.
.. Tumor suppressor gene E-cadherin and its role in
normal and malignant cells
41(77). Christofori, G. and H. Semb (1999), The role of the cell-adhesion
molecule E-cadherin as a tumour-suppressor gene. Trends Biochem Sci,
24(2), 73-6.,
42(78). Handschuh, G., et al. (1999), Tumour-associated E-cadherin mutations
alter cellular morphology, decrease cellular adhesion and increase cellular
motility. Oncogene, 18(30), 4301-12.
25(79). M.   Katoh,   “Epithelial­mesenchymal   transition   in   gastric   cancer

(Review),” International Journal of Oncology, vol. 27, no. 6, pp. 1677–1683,

2005
45(80). U. Cavallaro and G. Christofori,(2004), “Cell adhesion and signalling
by cadherins and Ig-CAMs in cancer,” Nature Reviews Cancer, vol. 4, no. 2,
pp. 118–132.

81. Figueiredo J, Melo S, Carneiro P, et al Clinical spectrum and pleiotropic nature

of CDH1 germline mutations Journal of Medical Genetics 2019;56:199-208.